[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Kim MH, Chang HM, Kim TW, Lee SK, Park JS, Kim YH, Lee TY, Jang SJ, Suh CW, Lee TS, Kim SH, Lee SG: EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model. J Korean Med Sci; 2009 Jun;24(3):474-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model.
  • Cancer (KIGB-5) cells were given intravenously to produce hematogenous metastatic lung lesions which were treated with EC-18 at 10, 25, and 50 mg/kg/day respectively.
  • EC-18 treated groups showed only a few microscopic lung lesions and no evidence of metastatic lesion with highest dose whereas widespread gross lung lesions were observed in untreated control.
  • TLR-4 mRNA and protein expression, measured by reverse transcriptase PCR (RT-PCR), real-time quantitative PCR and western blot analysis, showed suppression of TLR-4 expression in KIGB-5 cells treated with EC-18 compared with control.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biliary Tract Neoplasms / drug therapy. Glycerides / therapeutic use
  • [MeSH-minor] Animals. Cricetinae. Cytokines / metabolism. Diglycerides. Female. Lung / pathology. Neoplasm Metastasis. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. Toll-Like Receptor 4 / genetics. Toll-Like Receptor 4 / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] Dev Biol. 2008 Mar 1;315(1):72-88 [18206868.001]
  • [Cites] J Med Invest. 2003 Feb;50(1-2):9-24 [12630564.001]
  • [Cites] Biol Cell. 2004 Feb;96(1):69-78 [15093129.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Biol Pharm Bull. 2004 Jul;27(7):1121-5 [15256752.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2004 Jul;52(7):874-8 [15256714.001]
  • [Cites] Cancer Res. 1988 May 1;48(9):2372-6 [3258541.001]
  • [Cites] J Immunol. 1988 May 15;140(10):3679-85 [2896213.001]
  • [Cites] Am J Physiol. 1993 Oct;265(4 Pt 1):C927-33 [8238317.001]
  • [Cites] JAMA. 1994 Mar 23-30;271(12):907-13 [8120958.001]
  • [Cites] Cell Immunol. 1995 Feb;160(2):257-63 [7720087.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Jan 4;9(1):59-64 [9990457.001]
  • [Cites] Immunol Lett. 1999 Mar 15;67(1):23-30 [10217202.001]
  • [Cites] Prog Lipid Res. 1999 Jan;38(1):1-48 [10396601.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1889-94 [16609995.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2611-7 [11980657.001]
  • (PMID = 19543512.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / 1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Diglycerides; 0 / Glycerides; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ PMC2698195
  • [Keywords] NOTNLM ; Anti-Tumor Effect / Biliary Cancer / EC-18 / TLR-4
  •  go-up   go-down


2. Santel A, Aleku M, Röder N, Möpert K, Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, Eisermann M, Löffler K, Fechtner M, Fisch G, Vank C, Schaeper U, Giese K, Kaufmann J: Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res; 2010 Nov 15;16(22):5469-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models.
  • PURPOSE: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models.
  • The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hematogenous metastasis to the target organ lung in four different preclinical mouse models.
  • EXPERIMENTAL DESIGN: Atu027 compared with vehicle or control small interfering RNA lipoplexes was tested in two experimental lung metastasis models (Lewis lung carcinoma, B16V) and spontaneous metastasis mouse models (MDA-MB-435, MDA-MB-231, mammary fat pad).
  • Different dosing schedules (repeated low volume tail vein injections) were applied to obtain insight into effective Atu027 treatment.
  • Primary tumor growth and lung metastasis were measured, and tissues were analyzed by immunohistochemistry and histology.
  • RESULTS: Intravenous administration of Atu027 prevents pulmonary metastasis.
  • In particular, formation of spontaneous lung metastasis was significantly inhibited in animals with large tumor grafts as well as in mice with resected primary mammary fat pad tumors.
  • CONCLUSION: Atu027 can be considered as a potent drug for preventing lung metastasis formation, which might be suitable for preventing hematogenous metastasis in addition to standard cancer therapy.
  • [MeSH-major] Carcinoma, Lewis Lung / prevention & control. Carcinoma, Lewis Lung / secondary. Disease Models, Animal. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. RNA Interference. RNA, Small Interfering / therapeutic use
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Drug Administration Schedule. Endothelial Cells / drug effects. Endothelial Cells / enzymology. Endothelial Cells / metabolism. Humans. Injections, Intravenous. Mice. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 21062934.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Atu027; 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


3. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J: Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res; 2004 Apr 15;64(8):2743-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.
  • Spontaneous and experimental metastasis can be effectively inhibited by the widely used anticoagulant heparin in different tumor models.
  • Whereas previous attention has focused on P-selectin-dependent tumor-cell-platelet interactions in blood-borne metastasis, we sought to address the potential contribution of endothelial P-selectin expression to adhesive events between the microvasculature and melanoma cells in vivo.
  • Transplantation of bone marrow from P-selectin-deficient into wild-type mice conveyed inhibition of ex-perimental melanoma metastasis.
  • However, the extent to which bone marrow-conferred lack of platelet P-selectin expression attenuated melanoma lung metastasis was significantly less than that seen in P-selectin-deficient mice, suggesting that endothelial P-selectin expression may additionally contribute to formation of hematogenous metastases.
  • Heparin not only inhibits P-selectin-mediated melanoma cell rolling but also attenuates melanoma metastasis formation in vivo, further supporting the concept that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.
  • [MeSH-major] Heparin / pharmacology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Melanoma / drug therapy. Melanoma / secondary. P-Selectin / blood
  • [MeSH-minor] Animals. Blood Platelets / metabolism. Cell Communication / drug effects. Cell Communication / physiology. Endothelium, Vascular / drug effects. Endothelium, Vascular / pathology. Humans. Male. Melanoma, Experimental / blood. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Melanoma, Experimental / secondary. Mice. Mice, Inbred C57BL. Neoplasm Transplantation


Advertisement
4. Yamamoto A, Yano S, Shiraga M, Ogawa H, Goto H, Miki T, Zhang H, Sone S: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer; 2003 Mar 1;103(6):822-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice.
  • The lung is the common target organ of hematogenous metastasis that restricts the prognosis of cancer patients.
  • MMPs play a pivotal role in metastasis by promoting tumor invasion and angiogenesis; therefore, a large number of MMPIs have been developed.
  • Our purpose was to determine the therapeutic efficacy of a selective-spectrum MMPI, ONO-4817 (inhibits MMP-2 and MMP-9 but not MMP-1), against established lung micrometastasis in combination with a cytotoxic anticancer drug, DOC, in a nude mouse model.
  • Human non-small cell lung cancer PC14PE6 (adenocarcinoma) or H226 (squamous cell carcinoma) cells, expressing MMP-2, MMP-9 and/or MMP-1, were injected i.v. into nude mice on day 0.
  • Monotherapy with ONO-4817 or DOC inhibited formation of lung metastasis by PC14PE6 and H226 cells.
  • In addition, combined use of ONO-4817 with DOC significantly suppressed the tumor burden of H226 and PC14PE6 cells in the lung and prolonged the survival of PC14PE6-bearing mice compared to ONO-4817 or DOC alone.
  • These therapies did not affect the body weight or food intake of tumor-bearing mice.
  • FIZ revealed that lung lesions, but not nontumor parenchyma of the lung, expressed gelatinolytic activity and that treatment with ONO-4817 abrogated the gelatinolytic activity in lung lesions.
  • These results suggest that the combined use of MMPIs with cytotoxic anticancer drugs may be helpful in the control of established lung micrometastasis by tumor cells expressing MMPs.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / prevention & control. Carcinoma, Squamous Cell / secondary. Lung Neoplasms / prevention & control. Matrix Metalloproteinase Inhibitors. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Phenyl Ethers / therapeutic use. Taxoids
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / therapeutic use. Drug Therapy, Combination. Humans. In Vitro Techniques. Injections, Intravenous. Mice. Mice, Nude. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12516105.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Matrix Metalloproteinase Inhibitors; 0 / N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide; 0 / Phenyl Ethers; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Fu K, Kobayashi A, Saito N, Sano Y, Kato S, Ikematsu H, Fujimori T, Kaji Y, Yoshida S: Alpha-fetoprotein-producing colon cancer with atypical bulky lymph node metastasis. World J Gastroenterol; 2006 Dec 21;12(47):7715-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein-producing colon cancer with atypical bulky lymph node metastasis.
  • All of the reported cases harboring synchronous hematogenous spread including liver and/or lung metastasis had a poor prognosis and died within 12 mo.
  • We here describe a 71-year old man with AFP-producing colon cancer who presented with an unusual bulky lymph node metastasis instead of hematogenous spread.
  • He underwent adjuvant chemotherapy in addition to curative surgical resection, which prolonged his survival.
  • [MeSH-major] Colonic Neoplasms. Lymphatic Metastasis. Neoplasm Recurrence, Local / prevention & control. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):826-31 [12794586.001]
  • [Cites] Surg Today. 1997;27(5):453-6 [9130351.001]
  • [Cites] Cancer Res. 1975 Apr;35(4):991-6 [46783.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):91-9 [7802141.001]
  • [Cites] Cancer. 1970 May;25(5):1091-8 [5443731.001]
  • (PMID = 17171806.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC4088059
  •  go-up   go-down


6. Ngan RK, Yiu HH, Cheng HK, Chan JK, Sin VC, Lau WH: Central nervous system metastasis from nasopharyngeal carcinoma: a report of two patients and a review of the literature. Cancer; 2002 Jan 15;94(2):398-405
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system metastasis from nasopharyngeal carcinoma: a report of two patients and a review of the literature.
  • BACKGROUND: Central nervous system (CNS) metastasis from nasopharyngeal carcinoma (NPC) is an extremely rare occurrence, although direct intracranial invasion is not infrequent in patients with NPC at a locally advanced stage.
  • METHODS: The clinical records of two such patients with NPC who were diagnosed with metastasis to the spinal cord (intradural) and to the occipital lobe, respectively, were reviewed.
  • RESULTS: Both patients had locally advanced disease at the time of presentation and were treated with neoadjuvant chemotherapy and radical radiotherapy.
  • Spread through cerebral spinal fluid was postulated for the patient with spinal cord metastasis, and hematogenous spread was postulated for the patient with brain metastasis.
  • The patient with brain metastasis died 6 months later of lung metastasis, whereas the other patient is still alive 40 months from the diagnosis of spinal metastasis.
  • CONCLUSIONS: Good symptom control and disease control can be achieved for patients with CNS metastasis after surgery with or without radiotherapy.
  • After aggressive therapy, the ultimate survival depends on control of extracranial disease.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. In Situ Hybridization. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11905411.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


7. Garg PK, Khurana N, Hadke NS: Subcutaneous and breast metastasis from asymptomatic gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2009 Apr;8(2):209-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous and breast metastasis from asymptomatic gallbladder carcinoma.
  • BACKGROUND: Though gallbladder carcinoma is associated with early lymphatic and hematogenous spread, the only common extra-abdominal site of metastasis is lung.
  • Gallbladder carcinoma metastasizing to breast and subcutaneous tissue is not known.
  • METHOD: This report describes an interesting and unusual case of asymptomatic gallbladder carcinoma presenting with subcutaneous and breast metastasis.
  • She was diagnosed as a case of metastatic adenocarcinoma of the gallbladder and palliative combination chemotherapy with gemcitabine and carboplatin was given.
  • But she developed jaundice and deteriorated dramatically in a short span of time.
  • No specific therapy could be started and she was given supportive treatment.
  • She died within three weeks of diagnosis due to hepatic encephalopathy.
  • CONCLUSIONS: This report highlights an unusual metastasis of gallbladder carcinoma to the breast and subcutaneous tissue presenting as multiple lesions, which has never been reported in the English literature.
  • These were unknown sites of metastasis for carcinoma of the gallbladder.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357037.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Ino K, Mitsui T, Nomura S, Kikkawa F, Mizutani S: Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature. Gynecol Oncol; 2001 Dec;83(3):601-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature.
  • BACKGROUND: Gestational choriocarcinoma is a malignant tumor that frequently metastasizes to the highly vascularized organs such as the lung, brain, and liver via hematogenous spread.
  • However, this tumor rarely metastasizes to the eye and only a few cases of metastasis to the choroid have been reported.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor, and a CT scan showed a metastatic tumor in the left lung.
  • A clinical diagnosis of metastatic gestational choriocarcinoma involving the choroid and lung was made.
  • The patient received 13 courses of combination chemotherapy, resulting in complete remission.
  • Radiotherapy and surgical treatment were unnecessary.
  • CONCLUSION: This is a very rare case of the successful treatment of gestational choriocarcinoma metastatic to the choroid using systemic chemotherapy alone.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Choroid Neoplasms / drug therapy. Choroid Neoplasms / secondary. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2001 Elsevier Science.
  • (PMID = 11733980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


9. Downey RJ: Non-small cell lung cancer with a solitary hematogenous metastasis. Thorac Surg Clin; 2004 May;14(2):265-9, vii-viii
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer with a solitary hematogenous metastasis.
  • The standard treatment for patients with stage IV non-small cell lung cancer (NSCLC) is chemotherapy.
  • Retrospective series suggest, however, that some patients with stage IV lung cancer with a solitary synchronous site of extrathoracic metastatic (M1) disease are effectively treated by resection of both the primary tumor and the meststasis.
  • Although these patients represent a small minority of those with stage IV lung cancer, it appears reasonable to consider highly selected patients with a solitary resectable metastasis from NSCLC for surgical resection of all evident disease or for chemotherapy without surgery.
  • Because of the results of the current author's trial, however, it is difficult to recommend the regimen of combined medical and surgical therapies used in the current protocol in the management of solitary M1 disease.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome


10. Gong W, Liu Y, Huang B, Lei Z, Wu FH, Li D, Feng ZH, Zhang GM: Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun; 2008 Feb 29;367(1):144-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor.
  • The interaction of integrin alphavbeta3 and its ligands are crucial for tumor metastasis.
  • The in vivo expressed CH50 suppressed the lung metastasis of circulating tumor cells, and prolonged the survival of mice after tumor cell inoculation.
  • These findings suggest a prospective utility of CH50 in the gene therapy for prevention of tumor metastasis.
  • [MeSH-major] Fibronectins / therapeutic use. Genetic Therapy. Integrin alphaVbeta3 / antagonists & inhibitors. Neoplasm Metastasis / drug therapy. Recombinant Proteins / therapeutic use. Signal Transduction / drug effects
  • [MeSH-minor] Animals. CDC2 Protein Kinase / metabolism. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Line, Tumor. Extracellular Matrix / metabolism. Fibrinogen / chemistry. Fibrinogen / metabolism. Focal Adhesion Kinase 1 / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Inbred C57BL. Survival Rate

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162175.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CH50 recombinant polypeptide; 0 / Fibronectins; 0 / Integrin alphaVbeta3; 0 / Recombinant Proteins; 9001-32-5 / Fibrinogen; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.11.22 / CDC2 Protein Kinase; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


11. Carmignani CP, Ortega-Perez G, Sugarbaker PH: The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol; 2004 May;30(4):391-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer.
  • New strategies combining maximal cytoreductive surgery with intraperitoneal and systemic chemotherapy have been used in an attempt to prolong survival with an acceptable morbidity and mortality.
  • The goal for treatment in all patients was complete local and distant cytoreduction.
  • Aggressive intraperitoneal and systemic chemotherapy was used.
  • The endpoint for all the analysis was survival from the time of definitive treatment at our Institution.
  • RESULTS: In addition to peritoneal carcinomatosis, 16 patients had liver metastases, six patients had lung metastases, four had liver and lung metastases and one had supraclavicular lymph-node metastases.
  • Median survival time (MST) for the entire group was 15.2 months.
  • CONCLUSION: A group of carefully selected patients with peritoneal carcinomatosis and distant metastases from colorectal cancer may benefit from cytoreductive surgery and intraperitoneal chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / surgery. Liver Neoplasms / surgery. Lung Neoplasms / surgery. Neoplasm Seeding. Neoplasms, Multiple Primary / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Mortality. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15063892.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Naito Y, Akeda K, Kasai Y, Matsumine A, Tabata T, Nagao K, Uchida A: Lumbar metastasis of choriocarcinoma. Spine (Phila Pa 1976); 2009 Jul 1;34(15):E538-43
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumbar metastasis of choriocarcinoma.
  • STUDY DESIGN: A case of lumbar metastasis of a choriocarcinoma is presented.
  • SUMMARY OF BACKGROUND DATA: Choriocarcinoma is a highly anaplastic malignancy derived from trophoblastic cells characterized by the secretion of human chorionic gonadotropin (hCG) and early hematogenous metastasis.
  • Although 2 cases of metastasis in lumbar and/or sacral vertebra have been reported, the efficacy of surgical treatment for the spinal metastasis of choriocarcinoma is not yet known.
  • METHODS: The clinical course, radiologic features, pathology, and outcome of the treatment of metastatic choriocarcinoma of the lumbar spine is reported.
  • After computed tomography-guided needle biopsy, a clinical and pathologic diagnosis of lumbar metastasis of choriocarcinoma was made.
  • Surgical resection of the localized L2 vertebra lesion was performed by total en bloc spondylectomy after a poor response to initial chemotherapy with methotrexate.
  • Postsurgically, the serum level of hCG explosively increased and local recurrences around the original L2 vertebra and epidural metastasis abruptly developed.
  • Lung metastases also occurred concurrently and progressed and the patient eventually died to the disease.
  • CONCLUSION: We have reported a rare case of lumbar metastasis of choriocarcinoma after a normal-term pregnancy.
  • This is the first report of lumbar metastasis of choriocarcinoma treated by spinal surgery.
  • Because surgical resection of a lumbar metastasis of choriocarcinoma involves a substantial risk of profuse hemorrhage, local recurrence and the spread of metastasis, multiagent chemotherapy in combination with radiotherapy should be preformed before surgical resection.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / blood. Biopsy. Chorionic Gonadotropin / blood. Chorionic Gonadotropin / secretion. Drug Therapy / methods. Drug Therapy / standards. Epidural Neoplasms / secondary. Fatal Outcome. Female. Humans. Hydatidiform Mole / complications. Hydatidiform Mole / physiopathology. Lung Neoplasms / secondary. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Pregnancy. Treatment Failure

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564760.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


13. De Gast B, Smit L, Haanen J, Bonfrer H: The biomarker serum S100B identifies responders and prolonged survival in stage IV melanoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):7519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased values (≥0.16 μg/l) probably reflect actual hematogenous dissemination and are correlated with early (in 1<sup>st</sup> year) distant metastasis and decreased survival compared to patients with normal S100B values.
  • METHODS: In a large series of patients (n=145) treated with chemotherapy (Temozolomide), serum S100B was determined at start, following 2 cycles of chemotherapy and in regular follow-up (1-4 years).
  • Follow-up showed that 29/33 developed an increased S100B after a median of 7 months.
  • The group was characterized by a high response rate (15/33 = 45%, 3 CR), presence of only 1 or 2 metastatic sites (85%), mostly soft tissue or lung metastases (30 and 33%) and prolonged survival (median 14m).
  • In addition patients with slightly elevated S100B (0.16-050 μg/l) but rapid normalization on chemotherapy (n=14) had a high response rate (11/14 = 79%, 5 CR), 1-2 metastatic sites (95%) and prolonged survival (median 17 m).
  • Patients with normal or normalized S100B following 2 cycles of chemotherapy (n=41) had a prolonged survival (15.4 months) and 20% achieved a durable remission.
  • These patients might benefit from intensive multi-modality treatment consisting of chemotherapy followed by surgery of (residual) metastases and immunotherapy to achieve durable CR.
  • Normal S100B in stage IV is not genetically determined and distant (microscopic) metastasis probably occurred in an earlier stage of the disease (e.g., stage IIC, III B/C) prior to surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Staniszewska I, Walsh EM, Rothman VL, Gaathon A, Tuszynski GP, Calvete JJ, Lazarovici P, Marcinkiewicz C: Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis. Cancer Biol Ther; 2009 Aug;8(15):1507-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis.
  • Structurally, viperistatin belongs to the disintegrin family of proteins, whereas VP12 is composed of two subunits VP12A and VP12B displaying amino acid sequence homology with heterodimeric C-lectin type proteins.
  • MV3 cells express collagen receptors to much higher extent than HS.939T and required the application of higher concentrations of inhibitors to block their adhesion to collagen types I and IV.
  • In an animal model of hematogenous metastasis of the mouse B16F10 cell line, the inhibitory effect of viperistatin and VP12 was only partial.
  • These data suggest that collagen receptors may be an interesting target for development of new anti-metastatic therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Integrin alpha1beta1 / antagonists & inhibitors. Integrin alpha2beta1 / antagonists & inhibitors. Lung Neoplasms / prevention & control. Melanoma / secondary. Melanoma, Experimental / secondary. Neoplasm Proteins / antagonists & inhibitors. Viper Venoms / therapeutic use. Viperidae / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Adhesion / drug effects. Cell Line, Tumor / drug effects. Cell Line, Tumor / pathology. Chromatography, High Pressure Liquid. Chromatography, Ion Exchange. Collagen / physiology. Conserved Sequence. Drug Screening Assays, Antitumor. Humans. K562 Cells / drug effects. Mice. Molecular Sequence Data. Sequence Alignment. Sequence Homology, Amino Acid

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502781.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01 CA100145
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Integrin alpha1beta1; 0 / Integrin alpha2beta1; 0 / Neoplasm Proteins; 0 / VP121 protein, Vipera paleastinae; 0 / Viper Venoms; 9007-34-5 / Collagen
  •  go-up   go-down


15. Numazaki R, Miyagi E, Konnai K, Ikeda M, Yamamoto A, Onose R, Kato H, Okamoto N, Hirahara F, Nakayama H: Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients. Int J Clin Oncol; 2009 Aug;14(4):344-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients.
  • BACKGROUND: Adequate treatment for extremely advanced endometrial cancer is unknown.
  • The purpose of this study was to clarify the prognosis of patients with stage IVB endometrial carcinoma and the validity of treatment.
  • Furthermore, we evaluated whether there was a connection between the prognosis and the site of metastasis.
  • METHODS: The prognoses of 55 patients with stage IVB endometrial carcinoma were studied with reference to the initial treatment method and the metastatic site at the time of the initial treatment.
  • RESULTS: The median survivals of the group of 35 patients who were initially treated with surgery and the group of 10 patients who underwent radiotherapy or chemotherapy as their initial treatment followed by surgery were 11.5 months and 9.5 months, respectively.
  • Furthermore, the prognosis of patients with lung metastasis was significantly better than that of patients with non-lung hematogenous metastasis; the median survival periods of these two groups were 18.5 months and 10.5 months, respectively (P = 0.014).
  • CONCLUSION: For operable patients, surgery as an initial treatment and reduction of the residual tumor size to less than 2 cm appeared to contribute to a better prognosis.
  • In addition, conservative initial treatment and the presence of non-lung hematogenous metastasis were poor prognostic factors.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Gynecologic Surgical Procedures
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Obstet Gynecol. 1992 Aug;80(2):204-8 [1635733.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):85-91 [10926785.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):142-6 [1592280.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):75-84 [6693054.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):34-8 [7821845.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] AJR Am J Roentgenol. 1976 Jan;126(1):148-54 [175674.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1737-40 [3115558.001]
  • [Cites] Gynecol Oncol. 1990 Aug;38(2):210-5 [2387538.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):363-7 [7835775.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1915-23 [4055452.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):89-96 [14692028.001]
  • (PMID = 19705246.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Cormio G, Martino R, Loizzi V, Resta L, Selvaggi L: A rare case of choroidal metastasis presented after conservative management of endometrial cancer. Int J Gynecol Cancer; 2006 Nov-Dec;16(6):2044-8
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of choroidal metastasis presented after conservative management of endometrial cancer.
  • Hematogenous dissemination from endometrial cancer is quite rare.
  • We report a 31-year-old woman who developed choroidal metastasis following conservative management of early-stage endometrial carcinoma.
  • Three years after hysterectomy for persistent endometrial carcinoma, she developed multiple metastatic disease (to both lungs and right pelvis), and while on treatment with paclitaxel and carboplatin, she complained of a rapid visual deterioration.
  • The patient refused further treatment and died 1 month after diagnosis of choroidal involvement.
  • In conclusion, this is the first reported case of choroidal metastasis from endometrial cancer and highlights the need to consider immunosuppressive treatment as an absolute contraindication to conservative fertility-sparing treatment in gynecological malignancies.
  • [MeSH-major] Choroid Neoplasms / pathology. Choroid Neoplasms / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177844.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


17. Nakagoe T, Ishikawa H, Sawai T, Tuji T, Ayabe H, Eida K, Nogawa T, Nakamura Y, Kunisaki T, Tobinaga K, Furukawa M, Ino M: Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer. Anticancer Res; 2000 Mar-Apr;20(2B):1069-75
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer.
  • In patients with nuclear DNA aneuploid tumors, the hematogenous recurrence rate after curative surgery was lower in Group B than in Group A (P = 0.0656).
  • CONCLUSIONS: Preoperative and postoperative adjuvant oral UFT, administered with MMC after curative resection, may be effective in preventing hematogenous recurrence in colorectal cancer patients with nuclear DNA aneuploidy tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Invasiveness. Prospective Studies. Survival Analysis. Tegafur / administration & dosage. Time Factors. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10810399.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] GREECE
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil
  •  go-up   go-down


18. De Pas TM, de Braud F, Catalano G, Putzu C, Veronesi G, Leo F, Solli PG, Brambilla D, Paganelli G, Spaggiari L: Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Ann Thorac Surg; 2007 Jan;83(1):231-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.
  • BACKGROUND: We have assessed the survival rate of patients with non-small cell lung cancer and synchronous hematogenous solitary metastasis identified with complete staging workup, including total body [18F]fluorodeoxyglucose positron emission tomography scan, and treated with a multidisciplinary approach.
  • METHODS: We examined the database of all patients who underwent surgery for primary non-small cell lung cancer in our institute.
  • The criteria required for inclusion in this analysis were diagnosis of non-small cell lung cancer with synchronous hematogenous solitary metastasis by staging workup with total body computed tomography scan and brain magnetic resonance if indicated, total body positron emission tomography scan, radical surgery for the primary tumors, local treatment of the solitary metastasis, and systemic chemotherapy administration.
  • The median overall survival was 26 months, and the median time to progression was 20 months; 6 patients were alive at the time of analysis, with a median follow-up of 30 months.
  • Four patients were tumor progression-free after 9, 18, 23, and 32 months from the start of their treatment.
  • CONCLUSIONS: The presentation of non-small cell lung cancer with a synchronous hematogenous solitary metastasis identified by [18F]fluorodeoxyglucose positron emission tomography containing complete staging workup is extremely rare.
  • This subset of patients can achieve long-term survival after a multidisciplinary treatment approach.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2007 Jan;83(1):234-5 [17184670.001]
  • (PMID = 17184669.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Kondo K, Fujino H, Miyoshi T, Ishikura H, Sakiyama S, Monden Y: Orthotopically implanted SCID mouse model of human lung cancer suitable for investigating metastatic potential and anticancer drug effects. Oncol Rep; 2004 Nov;12(5):991-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthotopically implanted SCID mouse model of human lung cancer suitable for investigating metastatic potential and anticancer drug effects.
  • To evaluate the effects of drugs in clinical settings, an animal model of lung cancer similar to clinical cancer is necessary.
  • Our previous studies described an SCID mouse model using orthotopic implantation of the human lung cancer cell line which mimicked the lymph node metastasis of patients with lung cancer.
  • In this study, we made animal models that reflected various metastatic forms of lung cancer in humans.
  • We applied our procedure to 6 lung cancer cell lines.
  • Suspensions of 2.0 x 10(4) cancer cells were injected into the left lung of SCID mice.
  • We evaluated the mRNA expressions of 52 proteins related to the metabolism of and resistance to anticancer drugs of each tumor cell line and its orthotopically implanted tumor using a customized cDNA array.
  • Three lung cancer cell lines had the potential of lymphogenous metastasis and 3 cell lines had the potential of hematogenous metastasis in this model system.
  • The A549 line showed multiple metastases, and Ma2 line showed solitary metastasis.
  • This model was similar to the metastatic form in patients with lung cancer.
  • The similar expression of proteins in each tumor cell line in vitro and implanted tumor in vivo gives an advantage in evaluating the effects of molecular-targeted drugs and the relationship between specific genes and tumor potential in preclinical studies.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Mice. Mice, SCID. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Transplantation. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492783.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


20. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma.
  • The prognostic relevance of blood vessel invasion (BVI) in non-small cell lung carcinoma (NSCLC) remains controversial, as is the question of whether its finding should influence therapeutic decisions after an R0 resection.
  • Local recurrence occurred in 10.7% of the patients, distant metastasis in 24.1%, and both forms of tumor progression simultaneously in a further 7.1%.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • Late metastasis is not typical of NSCLC.
  • The histological detection of BVI is of prognostic relevance and should be considered for inclusion in the staging criteria and indications for adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Zhang HW, Zhang L, Chen JH, Du JJ: [The clinical significance of vascular endothelial growth factor and intercellular adhesion molecule-1 expression in non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2005 Mar 15;43(6):354-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical significance of vascular endothelial growth factor and intercellular adhesion molecule-1 expression in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1), and their relationship to behaviors of the non-small-cell lung cancer.
  • METHODS: The study included 86 patients with non-small-cell lung cancer.
  • All patients were treated surgically and without preoperative radio- or chemotherapy.
  • RESULTS: The positive expression of VEGF was significantly correlated with the lymph node metastasis, TNM stage, prognosis and hematogenous tumor metastasis positively, but ICAM-1 was negatively.
  • CONCLUSIONS: The expression of VEGF and ICAM-1 correlates with the malignant behavior of non-small-cell lung cancer.
  • Examination of VEGF and ICAM-1 in non-small-cell lung cancer may help to evaluate its intensity of lymph node metastasis, TNM stage and prognosis.
  • VEGF and ICAM-1 may play an important role in the development and metastasis of non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Intercellular Adhesion Molecule-1 / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854337.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


22. Kobayashi H, Gonda T, Uetake H, Higuchi T, Enomoto M, Sugihara K: JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study. Int J Cancer; 2004 Dec 20;112(6):920-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study.
  • The lung is a frequent site of metastasis from colorectal cancer, but angiogenesis of lung metastases has not been clarified.
  • We investigated the microvascular structure of small lung metastases and the effect of JTE-522, a selective COX-2 inhibitor, on the angiogenesis of pulmonary metastases from colorectal cancer in rats.
  • The diameter of tumor vessels and the size of lung metastases significantly and positively correlated with neovascularization in the control group, but not in the JTE-522-treated groups.
  • JTE-522 also affected type of vasculature of metastases, which differed depending on their size.
  • JTE-522 interfered with the growth of hematogenous metastatic tumors by disrupting neovascularization.
  • JTE-522 may be one of the therapeutic agents for the treatment of hematogenous metastasis of colorectal cancer.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antineoplastic Agents / pharmacology. Benzenesulfonates / pharmacology. Colorectal Neoplasms / pathology. Isoenzymes / antagonists & inhibitors. Lung Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Oxazoles / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cyclooxygenase 2. Enzyme Inhibitors / pharmacology. Logistic Models. Male. Microcirculation / drug effects. Microscopy, Electron, Scanning / methods. Prostaglandin-Endoperoxide Synthases. Pulmonary Circulation / drug effects. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15386343.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Enzyme Inhibitors; 0 / Isoenzymes; 0 / Oxazoles; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


23. Kobayashi S, Okada S, Hasumi T, Sato N, Fujimura S: Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: report of a case. Surg Today; 2000;30(6):561-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: report of a case.
  • We describe herein the case of a 59-year-old-man with stage IV pulmonary large cell carcinoma and a giant brain metastasis, in whom two sublines with different growth characteristics and drug sensitivities in vitro were established from the primary tumor.
  • Disease-free survival for more than 5 years after surgery was achieved by combined-modality therapy together with surgery to remove the primary tumor, radiation to the brain metastasis, and chemotherapy to presumed hematogenous dissemination.
  • Subline 1 proliferated in a monolayer of epithelial-like cells, while subline 2 showed a floating colony pattern of proliferation, resembling the typical growth characteristics of small cell lung cancer (SCLC) cells in vitro.
  • Subline 2 was sensitive to a number of drugs, namely, vincristine (VCR), cyclophosphamide (CPM), adriamycin (ADR), and cisplatin (CDDP), whereas subline 1 was resistant to many drugs.
  • The patient was treated with a combination of 44 Gy of whole-brain irradiation and a number of cycles of chemotherapy comprised of ADR, VCR, and CPM, followed by CDDP, VCR, and CPM, based on the results of sensitivity testing of the subline 2 cells.
  • In conclusion, this case report serves to demonstrate that meticulous combined-modality treatment taking tumor heterogeneity in human cancers into account may be necessary to achieve breakthroughs in current cancer therapy for advanced lung cancer.
  • [MeSH-major] Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / therapy. Lung Neoplasms / mortality. Lung Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Jan;109(1):271-6 [8549197.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 7):32-41 [7610397.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):754-6 [718475.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1749-53 [6169424.001]
  • [Cites] Tohoku J Exp Med. 1992 Oct;168(2):375-86 [1306323.001]
  • [Cites] Cancer. 1986 Sep 1;58(5):1007-13 [3731033.001]
  • [Cites] Tohoku J Exp Med. 1998 Dec;186(4):313-22 [10328163.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):527-37 [7977175.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):278-83 [8625235.001]
  • [Cites] Int J Radiat Biol. 1990 Jun;57(6):1113-22 [1971838.001]
  • [Cites] Lung Cancer. 1994 Dec;11(5-6):393-400 [7704496.001]
  • [Cites] Cancer. 1986 Feb 15;57(4):804-7 [3002587.001]
  • [Cites] Cancer. 1996 May 1;77(9):1947-55 [8646697.001]
  • [Cites] Tohoku J Exp Med. 1989 Sep;159(1):1-14 [2554531.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):146-53 [8691861.001]
  • (PMID = 10883474.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Ito H, Nakayama H: [Surgical management of pulmonary metastases]. Gan To Kagaku Ryoho; 2010 Feb;37(2):200-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because lung metastasis from a solid malignant tumor is a distant and hematogenous metastasis, its prognosis is generally dismal.
  • Therefore, the indications of local therapy such as surgical resections of lung metastasis remain very controversial.
  • However, in some cases, the metastasis of tumor cells from the primary site can be confined to the lungs before systemic and disseminated disease.
  • Surgical resection could be a curative treatment at this stage of lung metastasis.
  • A smaller number of metastases, long disease-free survival time, and no lymph node metastasis are the predictive factors for good prognosis after resection of lung metastasis.
  • However, there have been no criteria for the indications of lung metastasectomies.
  • Indications and outcomes of surgical resection for lung metastasis depend on each primary malignancies.
  • Wedge resection of the lung is thought to be an appropriate procedure for the resection of metastatic lung tumors.
  • Video assisted thoracoscopic resection is now widely used, however, controversy persists about whether this technique is appropriate approach for the patients undergoing metastasectomy with curative intent because the lack of palpation may be a cause of missing small metastatic lung tumors despite the advent of high resolution CT.
  • There is no randomized trial assessing whether there is any difference in survival after metastasectomy with versus without manual lung palpation.
  • Recent progress of chemotherapy, such as FOLFOX for colorectal cancer, could change the indications and outcome of surgical resection of metastatic lung tumors.
  • In addition, newly developed radiofrequency ablation came to be performed as local therapy in some centers.
  • We should decide the timing of resection considering the schedule of chemotherapy, so close corporation of surgeons and physicians is essential for managing metastatic lung tumors.
  • [MeSH-major] Lung Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Catheter Ablation. Combined Modality Therapy. Humans. Pneumonectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154473.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Mafune KI, Tanaka Y, Takubo K: Autopsy findings in patients with esophageal carcinoma: comparison between resection and nonresection groups. J Surg Oncol; 2000 Jul;74(3):196-200
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis of patients with esophageal cancer is poor, despite attempts at aggressive multimodality treatment.
  • To yield some important information that could help to improve operative methods and multimodality treatments, we compared autopsy findings such as the extent of local and metastatic spread of cancer in resection (n = 33) and nonresection (n = 38) groups of patients who had had esophageal cancer.
  • The most frequent mode of metastasis was hematogenous, occurring in 51.5% of the resection cases and 63.9% of the nonresection cases.
  • Lymph-node metastasis was also observed frequently, being present in 51.5% of resection cases and 58.3% of nonresection cases.
  • The low incidence of localized disease suggests that esophagectomy, even though palliative in some cases, is effective as a treatment for esophageal cancer.
  • The high incidence of lymph-node and hematogenous metastasis after esophagectomy implies that more extensive lymph-node dissection and stronger adjuvant chemotherapy might be required.
  • [MeSH-minor] Aged. Aged, 80 and over. Autopsy. Cohort Studies. Combined Modality Therapy. Esophagectomy. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10951416.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


26. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung and intraabdominal organs are most frequently affected.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • The interval between the onset of the intracranial disease and the appearance of the metastasis varies from months to many years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y, Tagawa Y, Ayabe H: Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer; 2000 Jan;27(1):19-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Cathepsin B (CB) and matrix metalloproteinase-9 (MMP-9) in extirpated tissues of adenocarcinomas in non-small cell lung cancer from 90 cases was investigated immunohistologically, and the correlations between the extent of the expression and the clinicopathological features were assessed for investigating the process of tumor metastasis.
  • Sections were obtained from 10%-formalin-fixed and paraffin-embedded tissues.
  • A significantly higher extent of the CB expression was observed in the tissues of patients who showed postoperative recurrence of the tumor (P = 0.013).
  • Furthermore, the enzyme expressions were compared among different types of metastases.
  • Patients with higher extents of CB expression tended to show significantly higher rates of hematogenous and intrapulmonary metastases (P = 0.023 and P = 0.010, respectively).
  • Therefore, we suggested that evaluation of CB expression in the tumor tissue might be useful as a postoperative prognostic factor of pulmonary adenocarcinoma.
  • Especially, early cancer of T1N0 cases showing higher expression of CB may need postoperative adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Cathepsin B / biosynthesis. Lung Neoplasms / pathology. Matrix Metalloproteinase 9 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10672780.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.22.1 / Cathepsin B; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


28. Van Dam SD, Unni KK, Keller EE: Metastasizing (malignant) ameloblastoma: review of a unique histopathologic entity and report of Mayo Clinic experience. J Oral Maxillofac Surg; 2010 Dec;68(12):2962-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following data were gathered for reports that demonstrated well-differentiated ameloblastoma at the metastatic site: gender, ethnicity, age at time of primary tumor diagnosis, histologic pattern of primary tumor, anatomic sites of primary and metastatic tumors, interval from diagnosis of primary to diagnosis of metastasis, number of recurrences preceding metastasis, treatment responses to radiation and/or chemotherapy, presence of hypercalcemia, and length of survival after metastasis.
  • RESULTS: Twenty-seven valid reports of metastasizing (malignant) ameloblastoma were identified; 81% originated in the mandible, recurring on average 4 times before metastasis.
  • Lungs were the initial site of metastasis in 78% of reports, of which 71% were bilateral.
  • The average time from diagnosis of primary to metastasis was 18 years.
  • Over half of the patients were alive and had survived an average of 10 years since diagnosis of metastasis.
  • Those patients who had succumbed to their disease had an average survival time of 3 years after diagnosis of metastasis.
  • CONCLUSIONS: Metastasis of well-differentiated ameloblastoma occurs more rarely than previously believed.
  • Metastasis to the lungs bilaterally, by the hematogenous route, usually follows multiple failed attempts at primary tumor control.
  • Treatment of metastasizing (malignant) ameloblastoma should include close observation, thoracotomy with wedge resections, or experimental chemotherapeutic combinations.
  • [MeSH-major] Ameloblastoma / secondary. Lung Neoplasms / secondary. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20970910.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


29. Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME: Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol; 2002 Feb 15;20(4):982-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighteen of these patients developed cerebral metastases.
  • RESULTS: Median age at diagnosis of EOC was 52 years (range, 39 to 67).
  • All patients received at least one line of platinum-based chemotherapy; 56% (10 of 18) received more than one line of treatment; 17% (three of 18), two lines; 11% (two of 18), three lines; and 28% (five of 18), four lines.
  • The median treatment interval between each line of chemotherapy was 12, 18, and 4 months.
  • The median interval between diagnosis and CNS relapse was 46 months (range, 12 to 113), in comparison with 5 and 7.5 months for hematogenous relapse in lung or liver, respectively (P <.001).
  • An analysis of data from the literature also suggests that the incidence of cerebral metastases from EOC has increased over time.
  • An analysis of our data and the data from the literature suggests that the incidence of metastasis at this site in patients with EOC is increasing.
  • [MeSH-minor] Adult. Age of Onset. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Retrospective Studies


30. Lev-Chelouche D, Nakache R, Soffer D, Merimsky O, Klausner MJ, Gutman M: Metastases to the retroperitoneum in patients with extremity soft tissue sarcoma: an unusual metastatic pattern. Cancer; 2000 Jan 15;88(2):364-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases to the retroperitoneum in patients with extremity soft tissue sarcoma: an unusual metastatic pattern.
  • BACKGROUND: Extremity soft tissue sarcoma (STS) metastasizes preferentially to the lungs via the hematogenous route.
  • Metastases in extrapulmonary sites such as bone, brain, and subcutaneous tissues are observed less frequently.
  • The current study reviews the clinical course, management, and patient prognosis in such a pattern of metastasis.
  • Patient demographics, primary tumor site, other tumor sites, local recurrence, distant metastasis, treatment, and survival were analyzed.
  • All had primary STS of different histologic types and high histologic grade confined to a lower limb.
  • The retroperitoneal metastases were diagnosed between 6-120 months (mean, 45 months) after diagnosis of the primary sarcoma.
  • At that time, one patient had evidence of local recurrence of the primary tumor site, two patients had lung metastases, and one patient had diffuse bone metastases.
  • Two patients with recurrent retroperitoneal disease and one patient with retroperitoneal and lung metastases died despite systemic chemotherapy.
  • [MeSH-major] Retroperitoneal Neoplasms / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10640969.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


31. Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S, Fujii Y: Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol; 2008 Mar;3(3):265-9
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical prognostic factors and treatment of thymic carcinoma are not yet standardized.
  • Thirteen cases were considered to be unresectable or inoperable and received chemotherapy or chemoradiotherapy.
  • Postoperative irradiation was added as adjuvant therapy in the tolerable cases.
  • The most recent five cases received induction chemotherapy.
  • The 5-year survival rate was 47.5%, and median survival time (MST) was 49.0 months.
  • The cases with hematogenous metastasis demonstrated significantly poorer prognosis (p = 0.021), but lymphogenous metastasis was not a significant predictor of poor prognosis.
  • We suggest the importance of preoperative precise evaluation to exclude unresectable Masaoka stage IVb disease and expect preoperative chemotherapy or chemoradiotherapy to improve the respectability.
  • [MeSH-major] Thymoma / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Biopsy. Female. Follow-Up Studies. Heart Neoplasms / pathology. Humans. Japan / epidemiology. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neck. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant / methods. Retrospective Studies. Survival Rate. Thymectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317069.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Jäckel A, Bock M, Deichmann M, Waldmann V, Näher H: [Therapy of metastatic malignant uveal melanoma]. Hautarzt; 2001 Feb;52(2):98-103
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of metastatic malignant uveal melanoma].
  • [Transliterated title] Therapie des metastasierten malignen Uveamelanoms.
  • Hematogenous spread predominantly involves the liver and is often restricted to this organ for a long period.
  • Metastatic uveal melanoma is usually resistant to chemotherapeutic regimens established for the therapy of cutaneous melanoma.
  • Newer therapeutic modalities, such as local intra-arterial chemotherapy into the hepatic artery, perhaps combined with embolisation of feeder blood vessels of liver metastases, improves the prognosis of metastatic uveal melanoma.
  • Currently the nitrosourea derivate fotemustine is the drug of choice in the local hepatic and systemic treatment and seems to be superior to other chemotherapeutic agents.
  • Following the characterisation of primary uveal melanoma, we summarize the results of different treatment protocols for metastatic disease and give an overview of new strategies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chemoembolization, Therapeutic. Melanoma / secondary. Melanoma / therapy. Neoplasm Metastasis / therapy. Uveal Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Middle Aged. Multicenter Studies as Topic. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Prognosis. Skin Neoplasms / secondary. Skin Neoplasms / therapy. Time Factors

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244899.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; GQ7JL9P5I2 / fotemustine
  • [Number-of-references] 29
  •  go-up   go-down


33. Protzel C, Zimmermann U, Asse E, Kallwellis G, Klebingat KJ: Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report. J Neurooncol; 2002 Apr;57(2):141-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report.
  • Hematogenous metastases occur in over 50% of muscle-invasive transitional cell carcinomas (TCC) of the bladder.
  • Despite treatment (mostly surgery and radiotherapy), patients with brain metastases have an especially poor prognosis (median survival 2-5 months), making palliative treatment an important consideration.
  • We followed a 60-year-old man with multiple brain metastases who was ultimately treated with gemcitabine chemotherapy.
  • Two years later, he developed one brain metastasis and one lung metastasis.
  • Both metastases were resected and adjuvant chemotherapy was planned.
  • Before chemotherapy, the patient suffered from headaches and symptoms of hemiparesis.
  • The patient underwent whole-brain radiotherapy with 30 Gy, followed by four cycles of a 3-week gemcitabine (800 mg/m2 on days 1 and 8) schedule.
  • Another MRI showed a nearly complete response after four cycles of chemotherapy, with only small residual tumors remaining in the brain stem.
  • This impressive activity was accomplished without adverse side effects, suggesting that radiotherapy combined with gemcitabine monotherapy may be an excellent choice for palliative treatment of TCC of the bladder.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1998;33(4):392-5 [9612683.001]
  • [Cites] Urology. 1980 Aug;16(2):142-4 [7404907.001]
  • [Cites] Urology. 1992 Jan;39(1):17-20 [1728790.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] CA Cancer J Clin. 1989 Jan-Feb;39(1):3-20 [2492874.001]
  • [Cites] J Neurooncol. 1993 Jun;16(3):217-20 [8301346.001]
  • [Cites] CA Cancer J Clin. 1972 Jan-Feb;22(1):2-20 [4622675.001]
  • [Cites] J Urol. 1993 Mar;149(3):480-3 [8437250.001]
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):55-60 [10550827.001]
  • [Cites] J Urol. 1988 Oct;140(4):820-4 [3418810.001]
  • [Cites] J Urol. 1996 Jan;155(1):111-4 [7490804.001]
  • [Cites] J Urol. 1987 Jan;137(1):97-9 [3795376.001]
  • (PMID = 12125975.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 15
  •  go-up   go-down


34. Yamada N, Ohira M, Hirakawa K: [COX and study of cancer therapy]. Gan To Kagaku Ryoho; 2004 Aug;31(8):1147-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [COX and study of cancer therapy].
  • The increased expression of COX-2 in carcinoma tissue is found in gastric cancer, lung cancer and breast cancer as well as colon cancer.
  • Food and Drug Administration (FDA) approved administration of a COX-2 inhibitor to FAP patients.
  • COX-2 plays an important role in proliferation, invasion and metastasis of cancer.
  • COX-2 expression was reportedly enhanced in lung cancer by an anticancer agent and radiotherapy, and clinical application of a COX-2 inhibitor is attempted.
  • In addition, the experimental examination showed the inhibitory effect of a COX-2 inhibitor on hematogenous metastasis of colon cancer.
  • [MeSH-major] Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / biosynthesis. Neoplasms / enzymology. Prostaglandin-Endoperoxide Synthases / biosynthesis
  • [MeSH-minor] Adenomatous Polyposis Coli / drug therapy. Animals. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Breast Neoplasms / enzymology. Colonic Neoplasms / enzymology. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Female. Humans. Lung Neoplasms / enzymology. Male. Membrane Proteins. Mice. Mice, Knockout. Neoplastic Cells, Circulating / drug effects. Stomach Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15332534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 27
  •  go-up   go-down


35. Brown JR, Fuster MM, Li R, Varki N, Glass CA, Esko JD: A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clin Cancer Res; 2006 May 1;12(9):2894-901
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The binding of hematogenously borne malignant cells that express the carbohydrate sialyl Lewis X (sLe(X)) to selectin adhesion receptors on leukocytes, platelets, and endothelial cells facilitates metastasis.
  • To evaluate the efficacy of AcGnG-NM as an antimetastatic agent, we examined its effect on experimental metastasis and on spontaneous hematogenous dissemination of murine Lewis lung carcinoma and B16BL6 melanoma cells.
  • EXPERIMENTAL DESIGN: Tumor cells were treated in vitro with AcGnG-NM, and the degree of selectin ligand inhibition and experimental metastasis was analyzed in wild-type and P-selectin-deficient mice.
  • Conditions were developed for systemic administration of AcGnG-NM, and the presence of tumor cells in the lungs was assessed using bromodeoxyuridine labeling in vivo.
  • RESULTS: In vitro treatment of Lewis lung carcinoma cells with AcGnG-NM reduced expression of sLe(X)- and P-selectin-dependent cell adhesion to plates coated with P-selectin.
  • Treatment also reduced formation of lung foci when cells were injected into syngeneic mice.
  • CONCLUSION: Taken together, these data show that AcGnG-NM provides a targeted glycoside-based therapy for the treatment of hematogenous dissemination of tumor cells.
  • [MeSH-major] Disaccharides / therapeutic use. Glycosylation / drug effects. Melanoma, Experimental / pathology. Neoplasm Metastasis / prevention & control
  • [MeSH-minor] Animals. Antineoplastic Agents / chemistry. Antineoplastic Agents / therapeutic use. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675586.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112278; United States / NCI NIH HHS / CA / CA46462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Disaccharides
  •  go-up   go-down


36. Rossi S, Fiorentini G, Porcu G, Dentico P, Giustarini G, Bernardeschi P: Thyroid metastases from colon cancer case report in a long term survivor. J Exp Clin Cancer Res; 2003 Dec;22(4 Suppl):243-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colon cancer usually has an hematogenous spread to liver and lung: rarely, or in the case of most advanced disease, also brain and bone can be involved.
  • Thyroid metastasis is generally thought to be infrequent, breast and kidney cancer being the most frequent causes.
  • Herein we present the case of a man affected by liver metastasis from colon cancer, who developed unusual metastasis to thyroid.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Humans. Immunohistochemistry. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767939.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


37. Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y: Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy. Gynecol Oncol; 2007 Jun;105(3):757-61
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy.
  • OBJECTIVE: The purpose of the present study was to identify prognostic factors and recurrent patterns in pathologic parametrium-positive patients with stage IB-IIB cervical cancers treated by radical surgery and adjuvant therapy.
  • All these patients were treated postoperatively with adjuvant external whole pelvic irradiation, combination chemotherapy, or chemoradiotherapy.
  • Multivariate analysis revealed that vaginal invasion (p=0.0008), lymph node metastasis (p=0.002), and non-squamous histology (p=0.010) were independent indicators of the disease-free survival rates and that the vaginal invasion (p=0.009) and lymph node metastasis (p=0.011) were independent prognostic factors for the overall survival rates.
  • Disease recurrence was observed in 26 patients (31.0%) with a median time of 16.5 months (range, 5-59 months) from the surgery.
  • Hematogenous recurrences, including those in the lung, liver, and bone, were significantly higher in patients with non-squamous cell carcinomas (p=0.008).
  • CONCLUSIONS: Vaginal invasion and lymph node metastasis are independent indicators for disease-free and overall survival rates in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy.
  • Hematogenous recurrence may be evident in patients with non-squamous cell carcinomas.
  • [MeSH-major] Pelvic Floor / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433424.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Yu T, Gao QH, Wang XY, Wen YM, Li LJ: Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. Oncology; 2007;72(1-2):39-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the clinicopathologic features and therapeutic efficacy of malignant sublingual gland tumors.
  • Adenoid cystic carcinoma was mainly of the histologic type, and the other histologic classifications included mucoepidermoid carcinoma, myoepithelial carcinoma, polymorphous low-grade adenocarcinoma, adenocarcinoma and malignant pleomorphic adenoma.
  • Pulmonary metastasis and tumor recurrence were the main death reasons.
  • Eleven patients remain alive and well 34-312 months (median 108) after treatment.
  • Surgery is the main treatment option.
  • For adenoid cystic carcinoma, hematogenous spread is common, and pulmonary metastasis is a common pathway of the distant metastasis.
  • For some patients having lung metastasis, regional control is also important as there are some examples of patients surviving many years with asymptomatic pulmonary metastases.
  • Postoperative radiation therapy may be adjuvant for selected patients with high-stage and high-grade tumors, or when there is concern about the inadequacy of the resection.
  • The effect of chemotherapy remains elusive.
  • [MeSH-minor] Adult. Aged. Cause of Death. Female. Humans. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17998789.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Kakeji Y, Maehara Y, Sumiyoshi Y, Oda S, Emi Y: Angiogenesis as a target for gastric cancer. Surgery; 2002 Jan;131(1 Suppl):S48-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The expression of one of the angiogenic factors, vascular endothelial growth factor antigen, in gastric cancer cells can thus serve as a pertinent predictive factor for hematogenous invasion or metastasis, in addition to having prognostic value.
  • In in vivo experiments antiangiogenic agents with cytotoxic anticancer drugs formed a highly effective modulator combination for the treatment of the Lewis lung carcinoma against primary and metastatic disease.
  • CONCLUSIONS: Antiangiogenic agents may thus be valuable for long-term administration to maintain tumor dormancy because drug resistance does not develop, and these agents have a sustained effect.
  • As a target, antiangiogenic therapy may therefore be potentially able to prolong survival time of patients with gastric cancer.
  • [MeSH-major] Neovascularization, Pathologic / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Genetic Therapy. Humans

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11821787.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


40. [Tuberculosis in compromised hosts]. Kekkaku; 2003 Nov;78(11):717-22
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many new findings and useful reports for practical medical treatment are submitted; why these compromised hosts are predisposed to tuberculosis, tuberculosis diagnostic and remedial notes of those compromised hosts etc.
  • In 1980, Saiki and co-workers reported that host defense and delayed-type hypersensitivity response to M. tuberculosis was hampered in a mouse DM model established by injecting streptozotocin (Infect Immun.
  • Interestingly, levels of IFN-gamma and IL-12 in serum, lung, liver and spleen after infection were significantly reduced in DM mice when compared with those in control mice.
  • I calculated the odds of tuberculosis among gastrectomy patients to be 3.8 times that of appropriate controls.
  • It is easy to stay in the leaching lesion so that anti-tuberculosis drugs are much effective, and the patients recover easily.
  • However, if the treatment is delayed, it is fatally because hematogenous metastasis are easy to occur and become miliary tuberculosis.
  • With AIDS patients with tuberculosis, there are the following problems on the treatment. (1) The adverse reactions by antituberculosis drugs tend to occur in AIDS patients.
  • Eleven of 33 AIDS patients with tuberculosis had the adverse reactions (skin rash, fever, liver dysfunction) considered to be due to antituberculosis drugs.
  • It is a very large burden for the HIV infected persons to take simultaneously antituberculosis drugs, medicines for opportunistic infections, and anti-HIV medicines.
  • Since many medicines are taken, it is difficult to determine which drug is the cause once an adverse reaction occurs and all medicines should be often stopped. (2) The combined use with rifampicin (RFP) is difficult for the protease inhibitors and nonnuclear acid reverse transcriptase inhibitors.
  • RFP induces cytochrome P-450 in liver, accelerates the metabolism of some concomitant drug agents, and reduces blood concentration them remarkably.
  • When starting the two above-mentioned medicines during tuberculosis treatment, RFP should be changed to rifabutin (RFB) which has less induction of P-450 than RFP.
  • So, the treatment with EFV and RFP is recently chosen.
  • However, the monitor of the blood concentration of EFV is required, and the dose of EFV should be increased if it is a low value. (3) When a highly active antiretroviral therapy (HAART) is given to AIDS patients with tuberculosis, transient worsening of tuberculosis may develop after about two weeks. (ABSTRACT TRUNCATED)

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14672050.001).
  • [ISSN] 0022-9776
  • [Journal-full-title] Kekkaku : [Tuberculosis]
  • [ISO-abbreviation] Kekkaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement